Refine
Is part of the Bibliography
- yes (126)
Year of publication
Document Type
- Journal article (126) (remove)
Language
- English (126) (remove)
Keywords
- melanoma (18)
- Merkel cell carcinoma (12)
- therapy (6)
- psoriasis (5)
- PD-1 (4)
- dermatology (4)
- polyomavirus (4)
- uveal melanoma (4)
- Anaphylaxis (3)
- BRAF (3)
- Medizin (3)
- T cells (3)
- apoptosis (3)
- cell staining (3)
- children (3)
- drug adverse reaction (3)
- drug allergy (3)
- drug hypersensitivity (3)
- immune checkpoint blockade (3)
- immunohistochemistry (3)
- B-cell lymphoma (2)
- COVID-19 (2)
- CTLA-4 (2)
- Germany (2)
- Human papillomavirus (2)
- Immunotherapy (2)
- Merkel cell polyomavirus (2)
- PD-L1 (2)
- Th17 (2)
- allergy (2)
- anaphylaxis (2)
- angiogenesis (2)
- biologics (2)
- bullous pemphigoid (2)
- diagnosis (2)
- immunology (2)
- immunotherapy (2)
- inflammation (2)
- large T antigen (2)
- machine learning (2)
- mastocytosis (2)
- melanomas (2)
- miRNA (2)
- multiple sclerosis (2)
- pemphigus (2)
- pemphigus foliaceus (2)
- pemphigus vulgaris (2)
- penicillin allergy (2)
- penicillin hypersensitivity (2)
- peptide vaccination (2)
- polymavirus (2)
- treatment resistance (2)
- tumor (2)
- urticaria (2)
- A375 (1)
- ACE inhibitor (1)
- ARCI (1)
- ARCI EM type III (1)
- Allergy (1)
- Apoptosis (1)
- B cells (1)
- B-cells (1)
- B7-H1 Antigen (1)
- BARF-mutated melanoma (1)
- BP180 (1)
- BRAF mutation (1)
- BRAF mutations (1)
- BRN-3A (1)
- Background Epithelioid haemangioma (1)
- Basophil activation test (1)
- Becker naevus (1)
- Becker naevus syndrome (1)
- Beta-blocker (1)
- Bowen’s disease, periungual (1)
- Bullous pemphigoid (1)
- CD10 (1)
- CD105 antigen (1)
- CD274 (1)
- CD30 (1)
- CD34 antigen (1)
- CD8(+) (1)
- COX2 expression (1)
- CRISPR (1)
- CTLA-4 Antigen (1)
- Ca\(^{2+}\) signalling (1)
- Cancer Cell (1)
- Clinical trials (1)
- Covid-19 (1)
- Crohn disease (1)
- Cutaneous lymphoma (1)
- Cutaneous metastatic Crohn’s disease (1)
- Cx43 (1)
- DNA (1)
- DNA damage (1)
- DNA repair (1)
- Desmoplakin (1)
- Diagnose (1)
- Double sensitization (1)
- Drug Therapy, Combination (1)
- Drug allergy (1)
- Drug reaction (1)
- EBER in situ hybridization (1)
- EGR1 (1)
- ERBB receptors (1)
- EVER1 (1)
- EVER2 (1)
- Enoxaparin (1)
- Epigenetic regulation (1)
- Field sting (1)
- Flt3L (1)
- FoxO3 (1)
- G Protein (1)
- GNA11 (1)
- GNAQ (1)
- GSK3 (1)
- HDAC (1)
- HT29 cells (1)
- Hautkrebs (1)
- Heparin (1)
- Hippo signaling (1)
- Histone deacetylase (1)
- Honey bee (1)
- Hymenoptera venom (1)
- Hypersensitivity (1)
- IFN (1)
- IL‐10 (1)
- Immediate-type (1)
- Immune-related adverse event (1)
- Immunoadsorption (1)
- Immunoapheresis (1)
- Immunoglobulin E (1)
- Ipilimumab (1)
- JAK2 (1)
- Juvenile biventricular cardiomyopathy (1)
- Kaposi sarcoma (1)
- Kerinokeratosis papulosa (1)
- Krebs <Medizin> (1)
- Krüppel-like factor (1)
- LIF (1)
- LRIG1 (1)
- LSD1 (1)
- Large T antigen (1)
- Lysine-specific methylase (1)
- MCC (1)
- MCPyV (1)
- MCV-negative (1)
- MHC class I chain-related protein (1)
- Mastocytosis (1)
- Melanoma (1)
- Minimal change disease (1)
- Molecular imaging (1)
- Mycobacterium marinum (1)
- NIPAL4 (1)
- NRF2 (1)
- Nail unit (1)
- Nekrose (1)
- Nfatc1 (1)
- Nivolumab (1)
- Non-steroidal anti-inflammatory drug (1)
- P53 (1)
- PD‐L1 (1)
- PEComa (1)
- PIK3CA mutations (1)
- PRAME (1)
- Palmoplantar keratoderma (1)
- Pathologic neovascularization (1)
- Pityriasis lichenoides (1)
- Positron emission tomography (1)
- Programmed Cell Death 1 Receptor (1)
- Pseudo-allergy (1)
- RNA modification (1)
- RNA probe (1)
- Raman (1)
- Relapse (1)
- Risk factor (1)
- S2k guidelines (1)
- SARS-CoV-2 (1)
- SERS (1)
- STAT3 (1)
- Skin (1)
- Skin Neoplasms (1)
- Somatostatin receptor expression (1)
- Stevens-Johnson syndrome (1)
- Sturge-Weber syndrom (1)
- Sunitinib (1)
- T antigen (1)
- T-antigen (1)
- T-antigens (1)
- T-cell reactivity (1)
- TNF alpha (1)
- TP53 (1)
- TRRAP (1)
- Tr1 (1)
- Treatment failure (1)
- Tregs (1)
- Tubulin (1)
- Tyrosine kinase inhibition (1)
- United States (1)
- V. saphena magna (1)
- Vespula (1)
- Waxy papulosis of childhood (1)
- XPA (1)
- Y-box binding protein 1 (1)
- YTHDF1 (1)
- acitretin (1)
- activation (1)
- adalimumab (1)
- adjuvant treatment (1)
- advanced cutaneous squamous cell carcinoma (1)
- adverse drug reaction (1)
- adverse event (1)
- age (1)
- agranulocytosis (1)
- akt (1)
- algorithm (1)
- allergies (1)
- allotype (1)
- aluminum granuloma (1)
- amoxicillin (1)
- ampicillin (1)
- anergy (1)
- angioedema (1)
- antagomiRs (1)
- antibiotic (1)
- antibody–drug conjugates (1)
- antitumor immunity (1)
- artesunate (1)
- aspirin‐exacerbated respiratory disease (1)
- at-home sampling (1)
- atherosclerosis (1)
- autoantibodies (1)
- autoimmune disease (1)
- autoimmune diseases (1)
- autoimmune skin blistering disease (1)
- avelumab (1)
- bee (1)
- biomarker (1)
- biosimilar (1)
- bleomicina (1)
- bleomycin (1)
- blisters (1)
- blood (1)
- bone (1)
- breast cancer (1)
- brown band (1)
- buildup phase (1)
- bullae (1)
- c-flip (1)
- cDC2 subset (1)
- cancer (1)
- cancer microenvironment (1)
- cancer patients (1)
- cancer treatment (1)
- cartilage (1)
- case report (1)
- cell cycle (1)
- cell death (1)
- cell membranes (1)
- cell rich blue nevus (1)
- cell viability testing (1)
- cell-death (1)
- cemiplimab (1)
- cesioflammea (1)
- checkpoint blocker (1)
- checkpoint inhibitor therapy (1)
- chemokine (1)
- chromatin regulator (1)
- cicatricial pemphigoid (1)
- classification (1)
- collodion baby (1)
- combined targeted therapy (1)
- common blue nevus (1)
- comorbid diseases (1)
- comorbidity (1)
- congenital melanocytic nevi (1)
- conversion (1)
- copy number variations (1)
- coronavirus disease 2019 (1)
- cultured fibroplasts (1)
- cutaneous PEComa (1)
- cutaneous T-cell lymphoma and Merkel cell carcinoma (1)
- cutaneous T-cell-lymphoma (1)
- cutaneous adverse events (1)
- cutaneous angiosarcoma (1)
- cutaneous lupus erythematosus (1)
- cutaneous lymphomas (1)
- dabrafenib (1)
- dapsone (1)
- dendritic cells (1)
- dermal melanocytosis (1)
- dermatite flagelada (1)
- differential gene expression (1)
- disease severity (1)
- domain (1)
- drug effectiveness (1)
- drug exanthema (1)
- drug monitoring (1)
- drug therapy (1)
- drug-induced liver injury (DILI) (1)
- eczematous dermatitis (1)
- efgartigimod (1)
- endemic pemphigus foliaceus (1)
- endothelium (1)
- environmental factors (1)
- eosinophils (1)
- epidermis (1)
- epigenetic reader (1)
- epigenetic silencing (1)
- epitranscriptome (1)
- exanthem (1)
- experience (1)
- expression (1)
- extracellular-regulated kinase 5 (1)
- family (1)
- fatty liver disease (1)
- ferroptosis (1)
- fixed drug eruption (1)
- flagellate dermatitis (1)
- flu-like symptoms (1)
- focal adhesion (1)
- fumaric acid esters (1)
- functional genetics (1)
- fungos shiitake (1)
- gene induction (1)
- genetic association (1)
- germline (1)
- glycogen synthase kinase 3 (1)
- gold nanoparticles (1)
- half-life (1)
- health economics (1)
- health insurance (1)
- health-care costs (1)
- heat shock response (1)
- hemangioma (1)
- hemorrhagic (1)
- henoch-schönlein purpura (1)
- hereditary alpha-tryptasemia (1)
- hidradenitis suppurativa (1)
- high-risk Prostate Cancer (1)
- histologic findings (1)
- histology (1)
- histone (1)
- histone methyltransferase PRDM8 (1)
- human (1)
- hydroxy-dabrafenib (1)
- hymenoptera (1)
- hypoplasia of fatty tissue (1)
- ichthyosis (1)
- immune cell infiltration (1)
- immune infiltration (1)
- immune suppression (1)
- immunohistochemistry techniques (1)
- immunosuppression (1)
- immunotherapeutics (1)
- improvement (1)
- in vivo (1)
- in-vitro (1)
- in-vivo (1)
- indirect costs (1)
- inflammation-induced tissue demage (1)
- inflammatory disease (1)
- inguinal lymph node dissection (1)
- injection site reactions (1)
- inpatients (1)
- interferon (1)
- interferon beta (1)
- interferon-\(\beta\) (1)
- interleukins (1)
- interview (1)
- ipilimumab (1)
- keratinocytes (1)
- keratosis (1)
- kidney cancer (1)
- knockout (1)
- lactate dehydrogenase (1)
- laminin 332 (1)
- large cell transformation (1)
- leg cramps (1)
- lesions (1)
- lichen planus (1)
- life (1)
- liver metastasis (1)
- long-term outcome (1)
- lower body (1)
- lumps (1)
- lung cancer (1)
- lymphocytes (1)
- lymphoid hyperplasia (1)
- lymphoma (1)
- mRNA (1)
- mTOR (1)
- m\(^6\)A (1)
- macro-morphology (1)
- malignancy (1)
- malignant melanoma (1)
- management (1)
- mechanotransduction (1)
- mediated apoptosis (1)
- medical students (1)
- melanin (1)
- melanocytes (1)
- melanocytic markers (1)
- melanoma cell (1)
- melanoma cells (1)
- melanoma malignancy (1)
- melanoma patients (1)
- membrane proteins (1)
- membrans proteins (1)
- mental health (1)
- mepacrine (1)
- metabolic disease (1)
- metastatic (1)
- methylation (1)
- miR-375 (1)
- micro-morphology (1)
- microRNA-221 (1)
- microvessel density (1)
- migraine (1)
- migration and invasiveness (1)
- mitochondrial DNA (1)
- mitogen-activated protein kinase (1)
- moderate (1)
- mouse model (1)
- mtDNA (1)
- mucous membrane pemphigoid (1)
- multicenter (1)
- multiple myeloma (1)
- mycosis fungoides (1)
- necrotic cell death (1)
- neural crest factors (1)
- neurologic disease (1)
- nivolumab (1)
- nucleotide excision repair (1)
- oesophagogastroduodenoscopy (1)
- oncodermatology (1)
- oncogene-induced senescence (1)
- orofacial granulomatosis (1)
- outpatients (1)
- over-the-counter drugs (1)
- p53 (1)
- pan-RCC (1)
- panel sequencing (1)
- patient preferences (1)
- patient survival (1)
- pediatric (1)
- peginterferon bet-1a (1)
- pemphigoid (1)
- perivascular epitheloid cell tumour (1)
- phakomatosis pigmentovascularis (1)
- phosphorylation (1)
- phthalazinone pyrazole (1)
- pityriasis rubra pilaris (1)
- plaque-type psoriasis (1)
- polymerase chain reaction (1)
- population pharmacokinetics (1)
- predictive marker (1)
- primary cutaneous follicular B-cell lymphoma (1)
- programmed cell death receptor-1 (1)
- programmed necrosis (1)
- protein kinase pathway (1)
- protein variant (1)
- pseudolymphoma (1)
- pustular exanthema (1)
- quinacrine (1)
- quinine (1)
- rare (1)
- re-induction (1)
- real-world data (1)
- regional recurrence (1)
- registry (1)
- regulatory T cell (1)
- reporter genes (1)
- resistance (1)
- response durability (1)
- responses (1)
- retinoblastoma protein (1)
- review (1)
- rhabdoid differentiation (1)
- rhabdoid melanoma (1)
- risk factor (1)
- satellitosis (1)
- secretion (1)
- senescence (1)
- severe acute respiratory syndrome coronavirus 2 (1)
- sex differences (1)
- shiitake dermatitis (1)
- shiitake mushrooms (1)
- shiitake-dermatite (1)
- signal inhibition (1)
- single nucleotide polymorphism (1)
- skin (1)
- skin cancer (1)
- skin carcinogenesis (1)
- skin neoplasms (1)
- skin reactions (1)
- skin squamous cell carcinoma (1)
- small interfering RNAs (1)
- smoking (1)
- somatic mutations (1)
- squamous cell (1)
- stress signaling (1)
- subtypes (1)
- suppression (1)
- suppressor cells (1)
- surgical and invasive medical procedures (1)
- survival (1)
- survivin (1)
- survivin T-cell reactivity (1)
- switching (1)
- systemic sclerosis (1)
- targeted sequencing (1)
- targeted therapy (1)
- tertiary lymphoid structures (1)
- toxic epidermal necrolysis (1)
- toxicity (1)
- trametinib (1)
- transcription factors (1)
- transcriptome (1)
- treatment options (1)
- triptan (1)
- tumor immunity (1)
- tumor microenvironment (1)
- tumor suppressor genes (1)
- tumor-draining lymph node (1)
- tumors (1)
- tumour immunology (1)
- tumourigenesis (1)
- utaneous adverse events (1)
- vascular endothelial growth (1)
- vasculitis (1)
- venereology (1)
- vesicles (1)
- vespula (1)
- viral carcinogenesis (1)
- virus (1)
- volumetric absorptive micro-sampling (VAMS) (1)
Institute
- Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie (126) (remove)
Sonstige beteiligte Institutionen
EU-Project number / Contract (GA) number
- 277775 (2)
Bullous pemphigoid is the most common autoimmune blistering disease in industrialized countries and particularly affects the elderly. In this patient population, comorbid diseases are frequent and may complicate management and treatment of bullous pemphigoid. A better understanding why distinct diseases are more frequent in bullous pemphigoid patients may lead to new pathophysiological insights and - as a consequence - result in better patient care. The association of bullous pemphigoid with neurological and psychiatric diseases is well known and confirmed by several case-control studies. Association with further diseases such as malignancy and metabolic diseases are still discussed controversially. In recent years new relationships between bullous pemphigoid and autoimmune as well as inflammatory skin diseases have been reported. This review provides a systematic overview on studies addressing comorbidity in bullous pemphigoid patients. Increasing the awareness of both, common and rare comorbid diseases, may enable clinicians to optimize patient support and individualized treatment of bullous pemphigoid.
Background
Severe acute respiratory syndrome coronavirus 2 is a virus affecting different organs and causing a wide variety and severity of symptoms. Headache as well as loss of smell and taste are the most frequently reported neurological manifestations of coronavirus disease 2019 induced by severe acute respiratory syndrome coronavirus 2. Here we report on a patient with chronic migraine and medication overuse headache, who experienced remarkable mitigation of migraine following coronavirus disease 2019.
Case presentation
For many years prior to the severe acute respiratory syndrome coronavirus 2 infection, a 57-year-old Caucasian male suffered from very frequent migraine attacks and for control of headaches he had been taking triptans almost daily. In the 16-month period before the outbreak of coronavirus disease 2019, triptan was taken 98% of the days with only a 21-day prednisolone-supported triptan holiday, which, however, had no longer-lasting consequences on migraine frequency. Upon severe acute respiratory syndrome coronavirus 2 infection, the patient developed only mild symptoms including fever, fatigue, and headache. Directly following recovery from coronavirus disease 2019, the patient surprisingly experienced a period with largely reduced frequency and severity of migraine attacks. Indeed, during 80 days following coronavirus disease 2019, migraine as well as triptan usage were restricted to only 25% of the days, no longer fulfilling criteria of a chronic migraine and medication overuse headache.
Conclusion
Severe acute respiratory syndrome coronavirus 2 infection might be capable of triggering mitigation of migraine.
Immune checkpoint blockade therapy is beneficial and even curative for some cancer patients. However, the majority don’t respond to immune therapy. Across different tumor types, pre-existing T cell infiltrates predict response to checkpoint-based immunotherapy. Based on in vitro pharmacological studies, mouse models and analyses of human melanoma patients, we show that the cytokine GDF-15 impairs LFA-1/β2-integrin-mediated adhesion of T cells to activated endothelial cells, which is a pre-requisite of T cell extravasation. In melanoma patients, GDF-15 serum levels strongly correlate with failure of PD-1-based immune checkpoint blockade therapy. Neutralization of GDF-15 improves both T cell trafficking and therapy efficiency in murine tumor models. Thus GDF-15, beside its known role in cancer-related anorexia and cachexia, emerges as a regulator of T cell extravasation into the tumor microenvironment, which provides an even stronger rationale for therapeutic anti-GDF-15 antibody development.
Background
Healthcare workers and medical students faced new challenges during the COVID-19 pandemic. Processes within many hospitals were completely disrupted. In addition, the face to face teaching of medical students was drastically reduced. Those at risk of developing mental health problems appear to be younger health care workers and women.
Objective
To investigate potential COVID-19 pandemic-related gender differences in psychological distress among medical students and physicians in their first years of practice.
Design and setting
An anonymous survey was carried out online between December 1, 2021, and March 31, 2022, at the Mannheim Medical Faculty and the Würzburg Medical Faculty, Germany, after obtaining informed consent. Primary outcome measures were changes in anxiety and depression symptoms using the Hospital Anxiety and Depression Scale (HADS), and changes in participants' current quality of life using the WHO Quality of Life BREF.
Results
The results show wave-like courses for perceived anxiety and burden overlapping with the course of the COVID-19 incidence. In comparison to men, women showed a significant higher increase in HADS (p = 0.005) and a reduced life quality (p = 0.007) after COVID-19. Both sexes showed different frequencies of the factors influencing quality of life, with the presence of a previous mental illness and mean anxiety having a significant higher negative impact in women.
Conclusion
Future and young female physicians reported a disproportionate higher burden during COVID-19 compared to their male colleges. These observations suggest an increased need for support and prevention efforts especially in this vulnerable population.
Merkel cell carcinoma (MCC) is frequently caused by the Merkel cell polyomavirus (MCPyV), and MCPyV-positive tumor cells depend on expression of the virus-encoded T antigens (TA). Here, we identify 4-[(5-methyl-1H-pyrazol-3-yl)amino]-2H-phenyl-1-phthalazinone (PHT) — a reported inhibitor of Aurora kinase A — as a compound inhibiting growth of MCC cells by repressing noncoding control region (NCCR)-controlled TA transcription. Surprisingly, we find that TA repression is not caused by inhibition of Aurora kinase A. However, we demonstrate that β-catenin — a transcription factor repressed by active glycogen synthase kinase 3 (GSK3) — is activated by PHT, suggesting that PHT bears a hitherto unreported inhibitory activity against GSK3, a kinase known to function in promoting TA transcription. Indeed, applying an in vitro kinase assay, we demonstrate that PHT directly targets GSK3. Finally, we demonstrate that PHT exhibits in vivo antitumor activity in an MCC xenograft mouse model, suggesting a potential use in future therapeutic settings for MCC.
Severe and prolonged liver damage in pityriasis rubra pilaris treated with acitretin: a case report
(2022)
Acitretin is a systemic retinoid that is used in dermatology for treatment of various inflammatory and especially hyperkeratotic diseases. Elevation of liver enzymes may occur occasionally but normally resolves spontaneously, at the latest after termination of acitretin. However, it can very rarely develop into a life-threatening adverse event including drug-induced liver injury (DILI). A 45-year-old man with classical pityriasis rubra pilaris, a frequently severe, inflammatory skin disease, was started on acitretin. After a seemingly harmless elevation of transaminases, a few weeks after initiation of acitretin, the patient experienced a dramatic course of liver injury with hepatic jaundice though acitretin was stopped immediately. Eventually, laboratory values recovered upon high-dose oral prednisolone therapy. Prescribing physicians should keep in mind that acitretin might induce severe liver injury. Even after termination of acitretin laboratory values should be monitored for a while in order to recognize symptomless but harmful drug-induced liver injury in time.
The best characterized polyomavirus family member, i.e., simian virus 40 (SV40), can cause different tumors in hamsters and can transform murine and human cells in vitro. Hence, the SV40 contamination of millions of polio vaccine doses administered from 1955–1963 raised fears that this may cause increased tumor incidence in the vaccinated population. This is, however, not the case. Indeed, up to now, the only polyomavirus family member known to be the most important cause of a specific human tumor entity is Merkel cell polyomavirus (MCPyV) in Merkel cell carcinoma (MCC). MCC is a highly deadly form of skin cancer for which the cellular origin is still uncertain, and which appears as two clinically very similar but molecularly highly different variants. While approximately 80% of cases are found to be associated with MCPyV the remaining MCCs carry a high mutational load. Here, we present an overview of the multitude of molecular functions described for the MCPyV encoded oncoproteins and non-coding RNAs, present the available MCC mouse models and discuss the increasing evidence that both, virus-negative and -positive MCC constitute epithelial tumors.
(1) Background: C-X-C Motif Chemokine Receptor 4 (CXCR4) and Fibroblast Activation Protein Alpha (FAP) are promising theranostic targets. However, it is unclear whether CXCR4 and FAP positivity mark distinct microenvironments, especially in solid tumors. (2) Methods: Using Random Forest (RF) analysis, we searched for entity-independent mRNA and microRNA signatures related to CXCR4 and FAP overexpression in our pan-cancer cohort from The Cancer Genome Atlas (TCGA) database — representing n = 9242 specimens from 29 tumor entities. CXCR4- and FAP-positive samples were assessed via StringDB cluster analysis, EnrichR, Metascape, and Gene Set Enrichment Analysis (GSEA). Findings were validated via correlation analyses in n = 1541 tumor samples. TIMER2.0 analyzed the association of CXCR4 / FAP expression and infiltration levels of immune-related cells. (3) Results: We identified entity-independent CXCR4 and FAP gene signatures representative for the majority of solid cancers. While CXCR4 positivity marked an immune-related microenvironment, FAP overexpression highlighted an angiogenesis-associated niche. TIMER2.0 analysis confirmed characteristic infiltration levels of CD8+ cells for CXCR4-positive tumors and endothelial cells for FAP-positive tumors. (4) Conclusions: CXCR4- and FAP-directed PET imaging could provide a non-invasive decision aid for entity-agnostic treatment of microenvironment in solid malignancies. Moreover, this machine learning workflow can easily be transferred towards other theranostic targets.
Blue nevus is a benign melanocytic lesion, typically asymptomatic and of unknown etiology. Several histologic and clinical variants have been distinguished, the most frequent being common blue nevus, cellular blue nevus, and combined blue nevus. Although melanocytic nevi with a satellite lesion are usually suggestive of locally advanced malignant melanoma, very few cases of blue nevi with satellite lesions have been reported. The diagnosis of common or cellular blue nevi is generally straightforward; however, the presence of structures such as irregular edges or satellitosis are highly suggestive for malignancy, and differential diagnoses such as locally advanced malignant melanoma and malignant blue nevus should be considered. Recurrent blue nevi can display atypical features not seen in the primary lesion, such as pleomorphism and mitotic activity. They usually tend to follow a benign course; however, in some cases, recurrence may indicate malignant transformation. We here report the unique case of a 64-year-old woman with a recurrent cellular blue nevus accompanied by satellite lesions. Such a biological behavior resulting in a clinical presentation as a melanoma-like lesion is a rarity in blue nevus and has not been described before.